Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 226

Sort by

Sort Order Select

Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood (2024) 144 (23): 2389–2401.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma Retreated with Daratumumab in Real-World Clinical Practice in the USA

Sikander Ailawadhi, Sarah M. Larson, Shannon Ferrante, Nicole Rafalko, Niodita Gupta-Werner, Jennifer S. Harper, Rohan Medhekar, Marjohn Armoon, Annelore Cortoos, Shuchita Kaila, Shebli Atrash

Blood (2024) 144 (Supplement 1): 2381.

https://doi.org/10.1182/blood-2024-199085

Published: 2024

Journal Articles

Design and Methodological Considerations for Real World Data-Derived Progression-Free Survival in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 3763.

https://doi.org/10.1182/blood-2024-199224

Published: 2024

Journal Articles

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC TM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Binod Dhakal, Andrew J. Yee, Paul G. Richardson, Sikander Ailawadhi, Saurabh Chhabra, Eli Muchtar, Jesús G. Berdeja, Shambavi Richard, Jeffrey V Matous, Urvi A. Shah, Mark A. Schroeder, Amro Ali, Leah Leahy, Riadh Lobbardi, Rong Chu, Eunju Hurh, Anthony S. Fiorino, Sagar Lonial

Blood (2024) 144 (Supplement 1): 3366.

https://doi.org/10.1182/blood-2024-204255

Published: 2024

Journal Articles

Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience

Blood (2024) 144 (Supplement 1): 1981.

https://doi.org/10.1182/blood-2024-208294

Published: 2024

Journal Articles

Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (AL) Amyloidosis

Sikander Ailawadhi, Asher A. Chanan-Khan, Jack Khouri, Costas K. Yannakou, Zi Chen, Yanyan Wang, Huanshan Guo, Hengbang Wang, Mingyu Li, Mohammad Ahmad, Dajun Yang, Yifan Zhai

Blood (2024) 144 (Supplement 1): 1022.

https://doi.org/10.1182/blood-2024-202713

Published: 2024

Journal Articles

Iopofosine I 131 in Previously Treated Patients with Waldenström Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM™)

Blood (2024) 144 (Supplement 1): 861.

https://doi.org/10.1182/blood-2024-200277

Published: 2024

Journal Articles

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Blood (2024) 144 (Supplement 1): 5166.

https://doi.org/10.1182/blood-2024-210518

Published: 2024

Journal Articles

Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma (MM) Patients: Real-World Learnings from a Large, Prospective Study

Jayla Mondy, Saurav Das, Dhaani Ailawadhi, Yaw Adu, Sikander Ailawadhi

Blood (2024) 144 (Supplement 1): 3771.

https://doi.org/10.1182/blood-2024-209052

Published: 2024

Journal Articles

Examining Discrepancies in Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Novel Therapies across Diverse Clinical Landscapes: An International Prospective Study

Sikander Ailawadhi, Yelak Biru, Solène Clavreul, Maite San Miguel, Nicolas Cormier, Anna Sato, Cathy Zeanah, James Farrell, Erinn Hoag Goldman, Rakesh Popat

Blood (2024) 144 (Supplement 1): 3658.

https://doi.org/10.1182/blood-2024-208007

Published: 2024

Journal Articles

Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes

Blood (2024) 144 (Supplement 1): 4728.

https://doi.org/10.1182/blood-2024-208736

Published: 2024

Journal Articles

Disparities in Multiple Myeloma (MM): Race/Ethnicity-Specific Sociodemographic and Economic Factors That May Drive Patient Decisions to Refuse Treatment

Firas Baidoun, Vivek Roy, Ricardo D. Parrondo, Andre Fernandez, Caitlin Flott, Taimur Sher, Rami Manochakian, Asher A. Chanan-Khan, Sikander Ailawadhi

Blood (2024) 144 (Supplement 1): 3790.

https://doi.org/10.1182/blood-2024-206308

Published: 2024

Journal Articles

Reducing Time Toxicity for Anti-B-Cell Maturation Antigen (BCMA) Bispecific Treatment: Evidence from Pivotal Single-Arm Trial Data on Teclistamab, Elranatamab, and Linvoseltamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, Timothy J. Inocencio, Zheng-Yi Zhou, Michael K. Xu, Jack Eales, Michelle Little, Peter Quon, Qiufei Ma

Blood (2024) 144 (Supplement 1): 2271.

https://doi.org/10.1182/blood-2024-199182

Published: 2024

Journal Articles

Prospective Patient Preference Study for Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Attributes and Factors Affecting Patient Shared Decision-Making in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) in the United States (USA)

Sikander Ailawadhi, Swetha Challagulla, Dominic Pilon, Yan Meng, Mei Xue, Yuxi Wang, Keri Yang

Blood (2024) 144 (Supplement 1): 2265.

https://doi.org/10.1182/blood-2024-202786

Published: 2024

Journal Articles

A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Sikander Ailawadhi, Antje Hoering, J Christine Ye, Brea Lipe, Thomas R. Chauncey, Krisstina Gowin, David Calverley, Sarah A. Holstein, Erica L. Campagnaro, Adam Rosenthal, Jack Aiello, Saad Z. Usmani, Vincent Rajkumar, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3381.3.

https://doi.org/10.1182/blood-2024-209626

Published: 2024

Journal Articles

Early Mortality in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Sociodemographic and Economic Factors Contributing to the Disparity

Firas Baidoun, Ricardo D. Parrondo, Vivek Roy, Andre Fernandez, Caitlin Flott, Taimur Sher, Rami Manochakian, Asher A. Chanan-Khan, Sikander Ailawadhi

Blood (2024) 144 (Supplement 1): 4723.

https://doi.org/10.1182/blood-2024-206351

Published: 2024

Journal Articles

Awareness Regarding Clinical Trials Among Patients with Multiple Myeloma (MM): A Systematic Study to Validate Online Platforms for Conducting Patient Surveys

Jay R. Hydren, Mason S. Barnes, Rachel M Jensen, Leyla Bojanini, Dhaani Ailawadhi, Saurav Das, Jennifer M. Ahlstrom, Sikander Ailawadhi

Blood (2024) 144 (Supplement 1): 7620.

https://doi.org/10.1182/blood-2024-203280

Published: 2024

Journal Articles

Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

Blood (2024) 144 (Supplement 1): 4614.

https://doi.org/10.1182/blood-2024-207408

Published: 2024

Journal Articles

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Patrick Hagen, Surbhi Sidana, Terri L. Parker, Brian A. Walker, Vaishali Sanchorawala, Jeffrey A. Zonder, Taxiarchis Kourelis, Anita D'Souza, Heather J. Landau, Adam Rosenthal, Antje Hoering, Sikander Ailawadhi, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3309.1.

https://doi.org/10.1182/blood-2024-208227

Published: 2024

Journal Articles

Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways

Blood (2024) 144 (Supplement 1): 6201.

https://doi.org/10.1182/blood-2024-205509

Published: 2024

NARROW

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma Retreated with Daratumumab in Real-World Clinical Practice in the USA

Design and Methodological Considerations for Real World Data-Derived Progression-Free Survival in Multiple Myeloma

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC TM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience

Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (AL) Amyloidosis

Iopofosine I 131 in Previously Treated Patients with Waldenström Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM™)

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma (MM) Patients: Real-World Learnings from a Large, Prospective Study

Examining Discrepancies in Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Novel Therapies across Diverse Clinical Landscapes: An International Prospective Study

Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes

Disparities in Multiple Myeloma (MM): Race/Ethnicity-Specific Sociodemographic and Economic Factors That May Drive Patient Decisions to Refuse Treatment

Reducing Time Toxicity for Anti-B-Cell Maturation Antigen (BCMA) Bispecific Treatment: Evidence from Pivotal Single-Arm Trial Data on Teclistamab, Elranatamab, and Linvoseltamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Prospective Patient Preference Study for Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Attributes and Factors Affecting Patient Shared Decision-Making in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) in the United States (USA)

A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Early Mortality in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Sociodemographic and Economic Factors Contributing to the Disparity

Awareness Regarding Clinical Trials Among Patients with Multiple Myeloma (MM): A Systematic Study to Validate Online Platforms for Conducting Patient Surveys

Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only